Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01721018
Other study ID # 1716-12
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received October 22, 2012
Last updated June 8, 2017
Start date October 2012
Est. completion date November 14, 2016

Study information

Verified date June 2017
Source Virttu Biologics Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HSV1716, an oncolytic virus, is a mutant herpes simplex virus (HSV) type I, deleted in the RL1 gene which encodes the protein ICP34.5.

Malignant mesothelioma is an aggressive, asbestos-related tumour of the pleural and peritoneal cavities. It is a rare cancer which occurs in individuals who have been exposed to asbestos, although it typically occurs decades after exposure (10-40 years later). Malignant pleural mesothelioma forms plaques that are distributed on the surface of the pleural space in the lung. Approximately 30% of patients require an indwelling pleural catheter for drainage of pleural effusions. In this patient group, the indwelling catheter may be used to facilitate loco-regional delivery of HSV1716 to the pleural space.

This study seeks to evaluate the safety and biological effects of single and multiple administrations of HSV1716 in the treatment of malignant pleural mesothelioma.


Description:

The study will be conducted in two parts. PART A is a single centre, single dose design, open label. Patients with inoperable malignant pleural mesothelioma will receive a single dose of HSV1716 by intrapleural administration. Delivery will be by direct administration via an indwelling catheter into the pleural cavity. PART B is a single centre, repeat dose design, open label. Two groups of three patients with inoperable malignant pleural mesothelioma will receive 2 (group 1) or 4 (group 2) single doses of HSV1716 at weekly intervals. Administration will be via an indwelling catheter into the pleural cavity.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date November 14, 2016
Est. primary completion date November 14, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with histologically proven malignant pleural mesothelioma

- Patients with disease which is not amenable to potentially curative resection

- Patients with pleural effusions and/or 'trapped lung' who (i) have an existing indwelling pleural catheter for draining of excess pleural fluid or (ii) who require the insertion of an indwelling pleural catheter to drain excess pleural fluid

- Patients with a performance status = 2 (ECOG)

- Age of = 18 years (at screening)

- Ability to give written informed consent as evidenced by signature on the patient consent form, to communicate well with the investigator and to comply with the expectations of the study

Exclusion Criteria:

- Patients likely to require palliative radio- or chemotherapy within 30 days

- Any evidence of uncontrolled cardiac or respiratory disease that would be a contra-indication for virus administration

- Any other serious medical or psychiatric disorder that would be a contra-indication for virus administration

- Acute active infection of any kind or other severe systemic disease or medical or surgical condition that is deemed significant by the principal investigator

- Patients with immunosuppressive disorders or on systemic steroids > 5mg prednisolone/day

- Pregnancy: women of childbearing potential not taking adequate contraception, and women who are breast feeding

- Previous treatment with investigational viral therapy products

- Administration of any unlicensed or investigational product within 8 weeks of entry to the study

- No prior or concurrent malignancy within 5 years other than basal cell carcinoma of the skin or in situ neoplasia of the cervix uteri

- Inadequate haematological function as defined by:

Haemoglobin (Hb) < 10g/dl, Neutrophil Count < 1.5 x 10e9/l, Platelets < 100 x 10e9/l

- Deranged liver function tests: serum bilirubin = 1.5 x upper limit of normal reference range for laboratory; transaminases = 5 x upper limit of normal reference range

- Patients with inadequate renal function: serum creatinine = 1.5 x upper limit of reference range for laboratory

- Patients whose indwelling catheter is not of the type approved by the sponsor for use in the study

- Outwith any of the inclusion criteria above or considered unsuitable for entry into the study in any other way at the discretion of the principal investigator

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
HSV1716 Intra-pleural delivery


Locations

Country Name City State
United Kingdom Queen Elizabeth Univeristy Hospital, NHS Greater Glasgow & Clyde Health Board Glasgow
United Kingdom Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust Sheffield South Yorkshire

Sponsors (1)

Lead Sponsor Collaborator
Virttu Biologics Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Tumour measurement as recorded by CT scans and assessed using the modified Response Criteria in Solid Tumors (RECIST) for MPM. CT scans at Baseline, day 29 and day 57.
Primary Safety and tolerability of HSV1716 given by single and repeat intrapleural administration in patients with inoperable malignant pleural mesothelioma. Dose limiting toxicities will be assessed at 28 days after last injection of HSV1716.
Secondary Obtain evidence of HSV1716 replication and lysis of malignant pleural mesothelioma cells through analysis of pleural fluid and serum samples for evidence of cell death and/or HSV1716 replication and/or changes in appropriate biomarkers. Samples will be collected at each outpatient visit up to day 29 (Part A), or day 50 (Part B).
See also
  Status Clinical Trial Phase
Recruiting NCT06037941 - Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma N/A
Completed NCT01675765 - Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Phase 1
Withdrawn NCT04201145 - Pembrolizumab + Defactinib In Pleural Mesothelioma Phase 1
Completed NCT03048474 - Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma Phase 2
Completed NCT02369198 - MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC Phase 1
Terminated NCT01870609 - Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT00886028 - Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Phase 2
Completed NCT00272558 - Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT02436733 - Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM Phase 2
Completed NCT04843007 - Alvopem® (Pemetrexed) Safety Assessment
Active, not recruiting NCT00797719 - Short Neoadjuvant Hemithoracic IMRT for MPM Phase 1/Phase 2
Completed NCT00386815 - Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Phase 2
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Completed NCT04775446 - Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Completed NCT01644994 - Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma Phase 1/Phase 2
Completed NCT01865045 - Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
Completed NCT00571298 - Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma Phase 1
Recruiting NCT01343264 - Trimodality Therapy for Malignant Pleural Mesothelioma N/A
Active, not recruiting NCT04162015 - A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Phase 1
Recruiting NCT04400539 - The IMmunotherapy Pleural 5-ALA PDT Phase 2